1.	Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: Not specified Sponsor: NCI, Other Protocol IDs: 95-024, P30CA008748, MSKCC-95024, NCI-V95-0685, NCT00002663
2.	Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes Phase: Phase II Type: Treatment Status: Active Age: 10 and over Sponsor: Other Protocol IDs: 25145-CADEN, CADEN, NCT00953420
3.	Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From A Normal HLA- Compatible Or Partially- Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies Phase: Phase II Type: Diagnostic, Treatment Status: Active Age: any age Sponsor: Other Protocol IDs: 11-130, NCT01498484
4.	Phase I Study of Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes in Patients Undergoing Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow Transplantation Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: BCM-H-6676, H 6676, BCM-ETNA, NCT00608309
5.	Cell Bank of Epstein Barr Virus Specific Cytotoxic T Lymphocytes Phase: Phase I Type: Treatment Status: Active Age: Over 12 months to 75 years Sponsor: Other Protocol IDs: 04/7-M, NCT01823718